Caribou Biosciences(CRBU)
Focus: Caribou Biosciences is a public CRISPR-based cellular engineering company focused on developing off-the-shelf CAR-T therapies for hematologic malignancies and autoimmune diseases. Founded in 2015 and headquartered in Berkeley, CA, the company operates as a mid-stage clinical-stage biotech with public market access.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
1-4 this month
Stable — net -4 jobs in 30d
0 added, 4 removed. Backfill posture.
Recent layoff filing — 87 affected
- 10/6/2026 — 2929 7th Street, Ste 105 Berkeley CA 94710, CA · 87 affected · Closure
Source: state DOL filings via Big Local News
Should You Work at Caribou Biosciences?
AI assessmentHigh-risk, high-reward opportunity for scientists and clinicians seeking frontier CRISPR/CAR-T expertise, but career continuity is severely threatened by impending organizational collapse.
Why Work Here
- Access to cutting-edge CRISPR technology platform and cellular engineering capabilities at the forefront of gene therapy innovation
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$10M
Pipeline & Clinical Trials
Caribou-sponsored investigational therapy
Lymphoma, Non-HodgkinClinical Trials (1)
NCT05332054Long-Term Follow-up Study
N/AHelp build intelligence for Caribou Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.